Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The ENCalmSocial Trial
NCT07193563Phase 2Completed
- Sponsor
- Engrail Therapeutics
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ENX-102 in Social Anxiety Disorder (SAD), sponsored by Engrail Therapeutics. Started Sep 2025; status: completed.
02
Drugs
ENX-102
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT07193563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193563.